Maris-Tech Ltd. — 2023 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter filing; the provided text does not give separate Q4 results. Financial statements are prepared under U.S. GAAP and reported in U.S. dollars.
Business context
Maris-Tech is an Israeli B2B developer and seller of miniature digital video and audio systems, including AI-enabled edge-computing products. Its customers and markets include defense, homeland security, drones, robotics, smart cities, autonomous vehicles and space. It sells standard products and customized systems; manufacturing and component assembly are outsourced.
Key financial results
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $4.03 million | $2.50 million | +61% |
| Gross profit | $1.93 million | $0.78 million | +146% |
| Gross margin | 47.8% | 31.3% | +16.5 percentage points |
| Operating expenses | $4.86 million | $4.47 million | +9% |
| Operating loss | $2.93 million | $3.68 million | Loss narrowed 20% |
| Net loss | $2.71 million | $3.69 million | Loss narrowed 27% |
| Net loss per share, basic and diluted | $0.34 | $0.49 | Improved |
| Net cash used in operating activities | $3.87 million | $4.86 million | Use decreased |
Revenue growth was attributed to higher sales to new and existing customers, particularly in Israel, and increased customer validation of defense products. Product sales were $3.99 million; NRE and proof-of-concept contracts and related services contributed $45,330. Interest on bank deposits contributed to 2023 net financial income of $220,006, versus net financial expense of $4,495 in 2022.
Liquidity, cash flow and debt
- At year-end, cash and cash equivalents were $2.05 million, short-term bank deposits were $3.15 million, and restricted deposits were $32,692. The cash-flow statement reports $2.08 million of cash, cash equivalents and restricted deposits; short-term bank deposits are separate.
- Working capital was $7.26 million at December 31, 2023. Current assets were $10.32 million and current liabilities $3.06 million. The filing’s MD&A describes 2022 working capital as a deficit of $10.44 million, but the balance sheet implies positive working capital of $10.44 million; this inconsistency should be checked.
- Operating cash outflow remained significant despite improving year over year. Receivables rose $1.38 million and inventory rose $978,000, absorbing cash; management says inventory was built to fulfill outstanding orders.
- Investing activities provided $5.82 million, largely from releasing short-term bank deposits. Financing activities used $120,000, mainly for share repurchases.
- Related-party loans totaled approximately $1.09 million at year-end: $499,000 current and $589,000 long-term. The loans are non-interest-bearing and repayment is scheduled over 24 monthly installments beginning February 2024, subject to available free cash. The company reported no long-term bank loans received in 2022 or 2023.
- Total liabilities were $4.44 million and shareholders’ equity was $6.89 million. Capital expenditures were approximately $90,500, down from $284,500 in 2022.
Material changes and operating developments
- Revenue increased 61%, while cost of revenue increased 22%; gross margin improved to 47.8% from 31.3%.
- R&D expense increased 3% to $1.05 million; sales and marketing rose 45% to $875,000, reflecting increased marketing and business-development activity. General and administrative expense rose 3% to $2.93 million.
- Israel generated $3.05 million, or about 76% of revenue, compared with $1.31 million in 2022. Australia contributed $469,000, while U.K. revenue declined to $447,000 from $836,000.
- Two customers represented 46.5% of 2023 revenue: Customer B 35.4% and Customer A 11.1%. Customer B’s share increased from 25.1% in 2022.
- The company repurchased 120,715 shares for $119,536 at an average price of $0.987 per share, completing its repurchase plan in March 2023. Year-end shares outstanding were 7,878,501.
- In 2023, Maris-Tech reported strategic cooperation agreements, including with Hailo Technologies, and new and repeat customer orders. The filing cites a $7.5 million Callisto order through an Australian partner, but does not clearly specify its timing or how much, if any, was recognized as 2023 revenue.
Outlook, risks and unusual items
- Management expects year-end 2023 cash, short-term deposits, anticipated receipts from existing orders and projected new-customer revenue to fund current operations and obligations for the next 12 months. This is not formal earnings guidance; the filing warns that additional capital may be needed and financing may not be available on acceptable terms.
- Backlog was approximately $9.76 million as of January 1, 2024 and $10.81 million as of March 20, 2024. Management expected part to be delivered and recognized in 2024 and the remainder in 2025. Backlog is not guaranteed revenue: customers may defer or cancel orders, and recognition depends on delivery and contract terms.
- Product development includes Jupiter Payload, expected for release in Q2 2024; Mars Sniper, expected in Q3 2024; and Uranus-AI and satellite-related development. These are management expectations, not assurances.
- The company has incurred losses since inception and reported a $10.90 million accumulated deficit. Management expects losses to continue until products reach commercial profitability.
- Management concluded disclosure controls and internal control over financial reporting were ineffective at December 31, 2023 because of insufficient U.S. GAAP/SEC reporting capacity and inadequate segregation of duties. Remediation efforts include hiring qualified finance personnel and developing accounting controls; the company says these steps may not fully resolve the weaknesses. The auditor did not provide an internal-control effectiveness opinion.
- Israel-based operations face risks from the Israel-Hamas war, regional instability, employee reservist call-ups, trade restrictions and potential supply or business disruption. The company stated operations had not been adversely affected as of the report date; war and terrorism losses are not covered by its commercial insurance.
- IIA grants carry royalty and technology-transfer conditions. The filing reports approximately $450,000 in royalties, including accumulated interest, outstanding as of March 20, 2024; moving grant-supported manufacturing or know-how outside Israel may require approval and could increase obligations.
- An investment in Parazero was sold at a loss, producing approximately $91,000 of 2023 financial expense. A related-party service agreement with Parazero also provides for $10,000 monthly plus VAT and commissions. The filing separately discloses $191,170 paid in 2023 to a mechanical-design service provider related to the CEO; amended terms were to be submitted for shareholder approval and ratification.
- The company reports no material litigation during the period and no current litigation. It has never paid dividends and does not expect to do so in the foreseeable future.
Most important facts for investors to verify
- Whether backlog—including the cited $7.5 million Callisto order—converts to delivered products, recognized revenue and collected cash on the expected schedule.
- Customer concentration, especially Customer B’s 35.4% share of 2023 revenue, and the durability of major defense and government orders.
- Cash runway and the effect of ongoing operating cash burn, receivable and inventory needs, and scheduled repayments of related-party loans.
- Progress in remediating material weaknesses and the timing and cost of establishing effective financial-reporting controls.
- The amount and terms of IIA royalties and any approvals or extra payments that could arise from transferring technology or manufacturing outside Israel.
- The working-capital inconsistency for 2022, and the reported treatment and timing of large orders relative to revenue recognition.